Corvus Pharmaceuticals
CRVS
10.41
-0.15
-1.42%
Corvus Pharmaceuticals
US · CRVS
#3339 by market cap
Listed 2016
10.41
-0.15
-1.42%
Live - 5344 symbols - heartbeat 517s ago
· 2026-10-08 08:12
Pre-market
10.13
-2.69%
After-hours
10.52
+1.06%
- Market cap
- 875.70M
- P/E (TTM)i
- -16.27
- P/Bi
- 3.89
- EPSi
- -0.53
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on CRVS?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 10.64M | 10.88M | 11.93M | 9.52M | 8.10M | 6.88M | 8.16M | 9.25M |
| Research & development | 38.59M | 37.98M | 31.83M | 29.12M | 24.47M | 16.53M | 19.39M | 33.72M |
| Operating profit | -49.22M | -48.85M | -43.76M | -38.63M | -32.57M | -23.41M | -27.55M | -42.97M |
| Pretax profit | -46.94M | -46.67M | -6.00M | -43.24M | -41.31M | -27.03M | -62.29M | -15.28M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -46.94M | -46.67M | -6.00M | -43.24M | -41.31M | -27.03M | -62.29M | -15.28M |
| Basic EPS | -2 | -2 | 0 | -1 | -1 | -1 | -1 | 0 |
| Diluted EPS | -1.71 | -1.59 | -0.20 | -1.03 | -0.89 | -0.56 | -1.02 | -0.53 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 2.47M | 2.39M | 2.12M | 2.28M | 3.70M | 3.33M |
| Research & development | 7.45M | 7.87M | 8.45M | 9.94M | 11.18M | 15.96M |
| Operating profit | -9.92M | -10.26M | -10.57M | -12.22M | -14.88M | -19.30M |
| Pretax profit | 15.19M | -8.00M | -10.16M | -12.32M | -13.69M | -17.96M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | 15.19M | -8.00M | -10.16M | -12.32M | -13.69M | -17.96M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.13 | -0.10 | -0.12 | -0.15 | -0.15 | -0.19 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 115.59M | 79.34M | 45.34M | 71.31M | 43.66M | 27.96M | 54.41M | 58.21M |
| Cash & ST investments | 114.60M | 77.98M | 44.26M | 69.45M | 42.30M | 27.15M | 51.96M | 56.75M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 118.23M | 83.65M | 85.53M | 109.46M | 68.24M | 45.55M | 68.91M | 71.12M |
| Total current liabilities | 7.03M | 10.23M | 12.15M | 9.69M | 10.75M | 6.87M | 35.40M | 9.38M |
| Short-term debt | -- | 878.00K | 1.08M | 1.05M | 1.23M | 1.37M | 185.00K | 403.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 7,896,000.00 | 12,535,000.00 | 13,381,000.00 | 12,293,000.00 | 12,125,000.00 | 6,869,000.00 | 36,339,000.00 | 9,914,000.00 |
| Total equity | 110.34M | 71.11M | 72.15M | 97.16M | 56.12M | 38.68M | 32.57M | 61.21M |
| Retained earnings | -170.47M | -217.15M | -223.14M | -266.38M | -307.69M | -334.72M | -397.01M | -412.29M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 45.49M | 75.78M | 66.94M | 58.21M | 239.95M | 220.97M |
| Cash & ST investments | 44.21M | 74.41M | 65.69M | 56.75M | 236.71M | 215.23M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 59.44M | 89.46M | 80.47M | 71.12M | 253.20M | 239.27M |
| Total current liabilities | 9.28M | 8.51M | 8.07M | 9.38M | 12.11M | 13.67M |
| Short-term debt | 319.00K | 355.00K | 379.00K | 403.00K | 428.00K | 454.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 10,113,000.00 | 9,233,000.00 | 8,706,000.00 | 9,914,000.00 | 12,516,000.00 | 13,946,000.00 |
| Total equity | 49.33M | 80.23M | 71.77M | 61.21M | 240.68M | 225.33M |
| Retained earnings | -381.82M | -389.82M | -399.97M | -412.29M | -425.99M | -443.94M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -40.99M | -37.32M | -34.78M | -36.72M | -27.02M | -23.94M | -25.42M | -32.80M |
| Depreciation & amortization | 847.00K | 743.00K | 632.00K | 460.00K | 367.00K | 151.00K | 85.00K | 105.00K |
| Free cash flow | -41.34M | -37.35M | -34.85M | -36.72M | -27.29M | -23.97M | -25.42M | -32.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 64.88M | 0 | 1.22M | 60.94M | 0 | 7.84M | 16.41M | 0 |
| Ending cash balance | 39.20M | 5.15M | 16.46M | 63.46M | 13.16M | 12.62M | 8.74M | 4.58M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -8.26M | -5.78M | -9.57M | -9.19M | -10.37M | -15.40M |
| Depreciation & amortization | 22.00K | 29.00K | 28.00K | 26.00K | 29.00K | 34.00K |
| Free cash flow | -8.30M | -5.89M | -9.57M | -9.22M | -10.47M | -15.98M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | 189.41M | 0 |
| Ending cash balance | 5.00M | 14.69M | 2.87M | 4.58M | 40.10M | 18.91M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -48.10 | -51.44 | -8.37 | -51.08 | -53.90 | -57.02 | -174.85 | -32.60 |
| ROA %i | -44.07 | -46.24 | -7.09 | -44.35 | -46.49 | -47.51 | -108.85 | -21.83 |
| ROIC %i | -50.44 | -52.02 | -8.79 | -49.33 | -51.79 | -54.73 | -173.88 | -37.12 |
| 5-year avg ROE %i | -- | -- | -46.12 | -42.03 | -42.58 | -44.36 | -69.04 | -73.89 |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 16.45 | 7.76 | 3.73 | 7.36 | 4.06 | 4.07 | 1.54 | 6.21 |
| Quick ratioi | 16.36 | 7.66 | 3.65 | 7.22 | 3.99 | 3.96 | 1.47 | 6.09 |
| Debt / assetsi | 0.00 | 3.81 | 2.70 | 3.33 | 3.81 | 3.02 | 1.63 | 1.32 |
| LT debt / equityi | -- | 3.25 | 1.71 | 2.68 | 2.45 | -- | 2.88 | 0.87 |
| Interest coveragei | -- | -- | -- | -2,881.73 | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -100.13 | -68.67 | -35.82 | -32.60 | -30.46 | -35.43 |
| ROA %i | -83.20 | -58.61 | -21.65 | -21.83 | -28.26 | -32.93 |
| ROIC %i | -101.34 | -70.72 | -40.58 | -37.12 | -32.83 | -38.59 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.90 | 8.91 | 8.29 | 6.21 | 19.81 | 16.16 |
| Quick ratioi | 4.79 | 8.78 | 8.18 | 6.09 | 19.65 | 15.88 |
| Debt / assetsi | 1.94 | 1.21 | 1.26 | 1.32 | 0.33 | 0.30 |
| LT debt / equityi | 1.69 | 0.91 | 0.88 | 0.87 | 0.17 | 0.12 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 08:12:11 · For reference only, not investment advice and not tailored to your situation.